Reviewer rewards from the NIH

In an effort to keep good peer reviewers coming back, the National Institutes of Health is letting "permanent" reviewers, who typically serve for four years on chartered study sections, submit their own R01, R21, and R34 grant applications at any time, disregarding standard deadlines. NIH spokesman Don Luckett told me the agency decided to adopt the change after receiving feedback from long-term reviewers that their service put them at a disadvantage by requiring them to review applications whi

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
In an effort to keep good peer reviewers coming back, the National Institutes of Health is letting "permanent" reviewers, who typically serve for four years on chartered study sections, submit their own R01, R21, and R34 grant applications at any time, disregarding standard deadlines. NIH spokesman Don Luckett told me the agency decided to adopt the change after receiving feedback from long-term reviewers that their service put them at a disadvantage by requiring them to review applications while preparing their own. Doing away with deadlines for these reviewers "is a big advantage," he said, "and we're hoping it will be an incentive for reviewers to sign up" to review applications. Luckett said that applications submitted outside of standard deadlines would be reviewed within 120 days of submission, the same approximate turnaround time as applications submitted by deadline. The NIH currently has approximately 4,000 reviewers who would qualify for this extended deadline. The NIH is in the midst of an in-depth look at ways to improve the peer review process. Click linkurl:here;http://www.the-scientist.com/news/display/54009/ to weigh in on some of the ideas the agency is considering. You can read more about the change in policy linkurl:here;http://grants1.nih.gov/grants/guide/notice-files/NOT-OD-08-026.html on the NIH's Web site.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies